336,360 Shares in Drugs Made In America Acquisition II Corp. $DMII Purchased by Lineage Point Capital LP

Lineage Point Capital LP acquired a new position in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 336,360 shares of the company’s stock, valued at approximately $3,330,000. Drugs Made In America Acquisition II makes up approximately 1.3% of Lineage Point Capital LP’s holdings, making the stock its 28th largest position.

Several other hedge funds have also recently bought and sold shares of DMII. Virtu Financial LLC acquired a new position in shares of Drugs Made In America Acquisition II in the 4th quarter valued at approximately $317,000. TENOR CAPITAL MANAGEMENT Co. L.P. acquired a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter worth approximately $14,850,000. Toronto Dominion Bank bought a new position in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $1,880,000. Sona Asset Management US LLC bought a new position in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $2,970,000. Finally, Millennium Management LLC acquired a new position in Drugs Made In America Acquisition II during the fourth quarter valued at approximately $14,850,000.

Drugs Made In America Acquisition II Stock Down 0.0%

Shares of NASDAQ:DMII opened at $10.10 on Friday. Drugs Made In America Acquisition II Corp. has a one year low of $9.86 and a one year high of $10.10. The company has a 50 day moving average of $10.04.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DMII. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Drugs Made In America Acquisition II currently has an average rating of “Sell”.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank?check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply?chain resiliency and related healthcare operations in the United States.